A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly ...

The CSF1R-blocking antibody axatilimab has shown promising clinical activity in chronic GVHD. In this phase 2, multinational, pivotal, randomized study, we evaluated axatilimab at three different ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing ...

Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier. In August, the FDA approved axatilimab (Niktimvo; Incyte) to treat chronic graft-versus-host disease ...

Abstract #S230.) Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients with Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of ...

Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host ...

More information: Daniel Wolff et al, Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease, New England Journal of Medicine (2024).DOI: 10.1056/NEJMoa2401537 Mohamad Mohty ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab ...

“The data being presented at EHA showcase the potential for revumenib and axatilimab to transform the treatment paradigm for patients with acute leukemia and chronic GVHD, respectively,” said Nick ...